Gereon Lauer

Title: The Innovations of Gereon Lauer

Introduction

Gereon Lauer is a notable inventor based in Radolfzell, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of vascular endothelial growth factor (VEGF) variants. With a total of 2 patents, Lauer's work focuses on innovative solutions for chronic wound treatment.

Latest Patents

Lauer's latest patents include the use of proteolysis resistant active VEGF. This invention involves modifying the amino acid sequence of VEGF, specifically replacing alanine at position 111 with proline. Additionally, the arginine at position 110 can be substituted with another amino acid. These modifications lead to derivatives of VEGF that can be utilized in nucleic acids, expression systems, and medicaments aimed at treating chronic wounds.

Career Highlights

Gereon Lauer is currently associated with Bayer Innovation GmbH, where he continues to push the boundaries of medical research and innovation. His work has been instrumental in advancing therapeutic options for patients suffering from chronic wounds.

Collaborations

Lauer collaborates with esteemed colleagues such as Sabine Eming and Thomas Krieg. Their combined expertise enhances the research and development efforts within their field.

Conclusion

Gereon Lauer's contributions to the field of biotechnology, particularly through his innovative patents, demonstrate his commitment to improving medical treatments. His work at Bayer Innovation GmbH and collaborations with other experts further solidify his impact in the industry.